Ben Tre Pharmaceutical JSC (STC:DBT) Return-on-Tangible-Equity: 0.00% (As of . 20)


STC:DBT Ben Tre Pharmaceutical JSC STC:DBT
13 GF Score
Price ₫12,700.00
! 1 Warning Sign
View Full Analysis

What is Ben Tre Pharmaceutical JSC Return-on-Tangible-Equity?

Ben Tre Pharmaceutical JSC STC:DBT -0.78% 13 Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 898 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 111358.46% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ben Tre Pharmaceutical JSC's annualized net income for the quarter that ended in . 20 was ₫ Mil. Ben Tre Pharmaceutical JSC's average shareholder tangible equity for the quarter that ended in . 20 was ₫ Mil. Therefore, Ben Tre Pharmaceutical JSC's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Ben Tre Pharmaceutical JSC's Return-on-Tangible-Equity or its related term are showing as below:

STC:DBT's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.88
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Ben Tre Pharmaceutical JSC  (STC:DBT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Ben Tre Pharmaceutical JSC Return-on-Tangible-Equity Related Terms

Ben Tre Pharmaceutical JSC Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Ben Tre Pharmaceutical JSC's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ben Tre Pharmaceutical JSC Return-on-Tangible-Equity Chart

Ben Tre Pharmaceutical JSC Annual Data
Trend
Return-on-Tangible-Equity

Ben Tre Pharmaceutical JSC Semi-Annual Data
Return-on-Tangible-Equity

STC:DBT vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ben Tre Pharmaceutical JSC Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Ben Tre Pharmaceutical JSC's Return-on-Tangible-Equity falls into.


STC:DBT
13GF Score
Ben Tre Pharmaceutical JSC STC:DBT
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ben Tre Pharmaceutical JSC Return-on-Tangible-Equity Calculation

Ben Tre Pharmaceutical JSC's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

Ben Tre Pharmaceutical JSC's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a Return-on-Tangible-Equity of 0.00% as of . 20. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 898 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's Return-on-Tangible-Equity too high?
Ben Tre Pharmaceutical JSC's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 898 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 898 companies for Return-on-Tangible-Equity. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ben Tre Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ben Tre Pharmaceutical JSC's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Ben Tre Pharmaceutical JSC's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ben Tre Pharmaceutical JSC Business Description

Address No. 6A3, National Highway 60, Phu Tan Ward, Vinh Long Province, Ben Tre, VNM
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
13GF Score

Get the complete analysis for STC:DBT

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫12,700.00
Price